

FDA clears the world's first AI solution for Pulmonary Embolism

16 May 2019 | News

Aidoc now leads the way in FDA approved AI solutions for radiologists



Aidoc, the leading provider of AI solutions for radiologists, was granted Food and Drug Administration (FDA) clearance for an additional product in its expanding suite of AI-based workflow orchestration solutions. The clearance is for Aidoc's Pulmonary Embolism (PE) solution that works with radiologists to flag and triage PE cases in chest CTs. The approval comes just weeks after Aidoc closed a \$27 million funding round, bringing its total funding to \$40million.

"In addition to the significant value provided to the department by Aidoc's ICH solution, we recently added the PE module to the workflow", says Dr. Pressman, Chair of Imaging at Cedars-Sinai Medical Center. "I was impressed by the fact that the coverage continuously grows, allowing us to add this product in the workflow of more radiologists, becoming part of our daily work. I was also pleased by the ability of the software to prioritize PE studies accurately."

"It is clear that AI will play a tremendous role in the future of radiology," said Daniel J. Durand, M.D., Chair of Radiology at LifeBridge Health. "Considering the complexity of vascular diagnosis, we are eager to see how Aidoc's solutions can benefit our pulmonary embolism patients and bring tomorrow's technology to LifeBridge Health, today." LifeBridge Health operates four hospitals in and around Baltimore, Maryland.

The new clearance, combined with Aidoc's other proven solutions, gives Aidoc the most clearances for deep learning solutions in radiology and positions it firmly at the forefront of making AI standard of care.

Aidoc's solutions analyze medical images directly after the patient is scanned and notify the radiologists of cases with suspected findings to assist with prioritization of time-sensitive, and potentially life-threatening cases. Aidoc cuts the time from scan to diagnosis for some patients from hours to under five minutes, speeding up treatment and improving prognosis.